Comprehensive treatment of adrenal cortical carcinoma

  • Jian-hua DENG ,
  • Han-zhong LI ,
  • Zhi-gang JI ,
  • Yu-shi ZHANG ,
  • Guang-hua LIU
Expand
  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Received date: 2017-03-14

  Online published: 2019-04-26

Abstract

Objective: To investigate the clinical and functional imaging examination and pathological features of adrenocortical carcinoma (ACC), in order to improve the diagnosis and treatment of ACC.Methods: The clinical data of 93 patients with ACC were analyzed retrospectively. Their diagnosis, surgical treatment and follow-up of mitotane medcine therapy were madeaccording to clinical manifestations, adrenal endocrine function determination, imaging examination characteristics and histopathological results.Results: Among the 93 patients, the age ranged from 11 to 76 years, with a median age of 48 years. The ratio of male to female was 1 ∶1.2. Twenty-four hours urinary free cortisol (UFC) elevated in 86 cases, adrenocorticotropic hormone (ACTH) decreased in 88 cases, blood F rhythm disappeared in 82 cases, and 31 cases of aldosterone increased. Thirty-six cases of sexual hormone increased. Neuron specific enolase (NSE) increased in 27 cases. Insulin-like growth factor-1 (IGF-1) increased in 26 cases. Seventy-six cases of high-dose dexamethasone suppression test (HDDST) and low-dose dexamethasone supression test (LDDST) were not suppressed separately. There were 62 cases of hypertension, and typical Cushing manifestations in 81 cases. Blood glucose elevated in 54 cases. Hypokalemia was in 21 cases and androgen secretion increased in 36 cases. The maximum diameter of the tumor was 3-17 cm, with 6 cases of adrenal central vein, renal vein and inferior vena cava tumor thrombus. The recurrence time was 1.2-5.0 years after operation. Metastasis and recurrence were in 56 cases during the follow-up, lung metastasis in 13 cases, liver metastasis in 17 cases, retroperitoneal lymph node metastasis in 9 cases, lumbar metastasis in 7 cases, ovarian metastasis in 3 cases, abdominal wall and incision implantation in 4 cases. Fifteen cases with distant metastasis. Seventy-seven patients were treated with radical adrenalectomy, and the other patients were treated with renal and adrenal resection on the same side of the kidney. There were 5 cases of adrenal tumor with vena cava tumor thrombus in the removal of the tumor, and the other for the partial resection of the vena cava in 3 cases. Regarding the clinical stage, stage I was in 39 cases, stage Ⅱ in 28 cases, stage Ⅲ in 16 cases and stage Ⅳ in 10 cases. The patients were followed up for 8-69 months, and 43 patients survived more than 5 years.Conclusion: Function imaging combined with clinical features and endocrine hormone levels have important roles in ACC early diagnosis. Radical excision is the only effective treatment. Adjuvant or adjuvant mitotane drug therapy can brused for the treatment of recurrence and metastasis ACC patients,. ACC is a tumor with high malignancy and poor prognosis.

Cite this article

Jian-hua DENG , Han-zhong LI , Zhi-gang JI , Yu-shi ZHANG , Guang-hua LIU . Comprehensive treatment of adrenal cortical carcinoma[J]. Journal of Peking University(Health Sciences), 2019 , 51(2) : 298 -301 . DOI: 10.19723/j.issn.1671-167X.2019.02.019

References

[1] Allolio B, Fassnacht M . Clinical review: adrenocortical carcinoma: clinical update[J]. J Clin Endocrinol Metab, 2006,91(6):2027-2037.
[2] Baudin E , Endocrine Tumor Board of Gustave Roussy.Adrenocortical carcinoma[J]. Endocrinol Metab Clin North Am, 2015,44(2):411-434.
[3] Koch CA, Pacak K, Chrousos GP . The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors[J]. J Clin Endocrinol Metab, 2002,87(12):5367-5384.
[4] Soon PSH, McDonald KL, Robinson BG , et al. Molecular markers and the pathogenesis of adrenocortical cancer[J]. Oncologist, 2008,13(5):548-561.
[5] Ng L, Libertino JM . Adrenocortical carcinoma: diagnosis, evaluation and treatment[J]. J Urol, 2003,169(1):5-11.
[6] Funder JW, Carey RM, Fardella C , et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2008,93(9):3266-3281.
[7] Caoili EM, Korobkin M, Francis IR , et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT[J]. Radiology, 2002,222(3):629-633.
[8] Mallin K, Phillips JL, Winchester DP . Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States[J]. Ann Surg Oncol, 2017,24(Suppl 3):617.
[9] Chang A, Glazer HS, Lee JK , et al. Adrenal gland: MR imaging[J]. Radiology, 1987,163(1):123-128.
[10] 江昌新, 曾智, 王婷 , 等. 肾上腺皮质疾病的临床病理学特点分析[J]. 中华泌尿外科杂志, 2012,33(3):165-170.
[11] Raymond VM, Everett JN, Furtado LV , et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer[J]. J Clin Oncol, 2013,31(24):3012-3018.
Outlines

/